poisar

Stock

60 Degrees Pharmaceuticals, Inc. SXTP

$1.49-0.67%

Overview

SXTP market data

Price History

SXTP price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$10.99
Diluted earnings per share over the trailing twelve months.
Beta
2.47
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.22 – $8.62
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $4 · P/B 0.62 · P/S 3.03.

Company News

10 captured
60 Degrees Pharmaceuticals shares are trading higher after the company announced it enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis.Benzinga · Jul 29, 2026, 8:57 PM
60 Degrees Pharmaceuticals Announces Enrollment Of Minimum 24 Patients Triggering Interim Analysis In Severe Babesiosis Tafenoquine Study, Results By October 6Benzinga · Jul 29, 2026, 8:13 PM
60 Degrees Pharmaceuticals Will Be Issued US Patent Number 12,691,107 Tomorrow Titled "METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA, FUNGUS, OR VIRUS BY ADMINISTRATION OF TAFENOQUINE".Benzinga · Jul 27, 2026, 7:58 PM
60 Degrees Pharmaceuticals Enters Exclusive Option Agreement With Florida State's Research Foundation Regarding IP To Develop Castanospermine For Multiple Tick-Borne DiseasesBenzinga · Jul 8, 2026, 12:15 PM
60 Degrees Pharma's B-Free Babesiosis Trial Clears Initial Safety Review, Advances After DSMB RecommendationBenzinga · Jul 1, 2026, 12:15 PM
60 Degrees Pharma Executes Patent Licensing Agreement With Florida State University To Commence Large-Scale Production Techniques To Extract, Purify Castanospermine From Seeds Of Australian Chestnut For Non-Prescription UsesBenzinga · Jun 11, 2026, 12:13 PM
60 Degrees Pharmaceuticals Says Co. May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028Benzinga · Jun 3, 2026, 9:10 PM
Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $3.7Benzinga · May 22, 2026, 12:00 PM
HC Wainwright & Co. Downgrades 60 Degrees to NeutralBenzinga · May 20, 2026, 5:10 PM
60 Degrees Q1 EPS $(1.28) Misses $(0.76) Estimate, Sales $76.377K Miss $435.000K EstimateBenzinga · May 15, 2026, 1:35 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock